NOVO-DIPIRADOL TAB 50MG TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

DIPYRIDAMOLE

Disponible desde:

NOVOPHARM LIMITED

Código ATC:

B01AC07

Designación común internacional (DCI):

DIPYRIDAMOLE

Dosis:

50MG

formulario farmacéutico:

TABLET

Composición:

DIPYRIDAMOLE 50MG

Vía de administración:

ORAL

Unidades en paquete:

100/1000

tipo de receta:

Prescription

Área terapéutica:

MISCELLANEOUS VASODILATATING AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0106621002; AHFS:

Estado de Autorización:

CANCELLED POST MARKET

Fecha de autorización:

2005-08-10

Ficha técnica

PRODUCT MONOGRAPH
Pr
NOVO-DIPIRADOL (dipyridamole) 25, 50, 75, 100 mg Tablets
Pr
DIPYRIDAMOLE FOR INJECTION (dipyridamole) 5 mg/mL, USP
Coronary Vasodilator
Inhibitor of Platelet Adhesion and Aggregation
Novopharm Limited
Date of Preparation:
30 Novopharm Court
October 26, 2006
Toronto, Ontario
M1B 2K9
Control No. 107491
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
3
WARNINGS AND
PRECAUTIONS.........................................................................................
4
ADVERSE
REACTIONS...........................................................................................................
5
DRUG INTERACTIONS
...........................................................................................................
8
DOSAGE AND
ADMINISTRATION.......................................................................................
9
OVERDOSAGE
.........................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 10
STORAGE AND
STABILITY.................................................................................................
11
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 11
PART II: SCIENTIFIC INFORMATION
...............................................................................
13
PHARMACEUTICAL
INFORMATION.........................................................